Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL?

Author:

Oort Quirien1,Dirven Linda23ORCID,Sikkes Sietske A M456,Aaronson Neil7,Boele Florien89ORCID,Brannan Christine10,Egeter Jonas11,Grant Robin12,Klein Martin13,Lips Irene M14,Narita Yoshitaka15ORCID,Sato Hitomi1516,Sztankay Monika11,Stockhammer Günther17,Talacchi Andrea18,Uitdehaag Bernard M J1,Reijneveld Jaap C119,Taphoorn Martin J B23

Affiliation:

1. Department of Neurology and Brain Tumor Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam , The Netherlands

2. Department of Neurology, Leiden University Medical Center , Leiden , The Netherlands

3. Department of Neurology, Haaglanden Medical Center , The Hague , The Netherlands

4. Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam , The Netherlands

5. Alzheimer Center, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam , The Netherlands

6. Vrije Universiteit Amsterdam, Faculty of Behavioural and Movement Sciences (FGB), Department of Clinical Developmental & Clinical Neuropsychology , Amsterdam , The Netherlands

7. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute , Amsterdam , The Netherlands

8. Leeds Institute of Medical Research, St James’s University Hospital , Leeds , UK

9. Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds , Leeds , UK

10. East & North Hertfordshire NHS Trust incorporating Mount Vernon Cancer Centre , Northwood , UK

11. Department for Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry II, Medical University of Innsbruck , Innsbruck , Austria

12. Department of Clinical Neurosciences, Western General Hospital , Edinburgh , UK

13. Department of Medical Psychology, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam , The Netherlands

14. Department of Radiation Oncology, Leiden University Medical Center , Leiden , The Netherlands

15. Department of Neurosurgery and Neuro-Oncology, National Cancer Center , Tokyo , Japan

16. Department of Nursing, Teikyo Heisei University , Tokyo , Japan

17. Department of Neurology, Innsbruck Medical University , Innsbruck , Austria

18. Department of Neurosurgery, Azienda Ospedaliera San Giovanni Addolorata , Roma , Italy

19. Department of Neurology, Stichting Epilepsie Instellingen Nederland (SEIN) , Heemstede, The Netherlands

Abstract

Abstract Background Neurocognitive impairments are common among brain tumor patients, and may impact patients’ awareness of performance in instrumental activities in daily life (IADL). We examined differences between patient- and proxy-reported assessments of the patient’s IADL, and whether the level of (dis)agreement is associated with neurocognitive impairments. Methods Brain tumor patients and their proxies completed the phase 3 version of the EORTC IADL-BN32 questionnaire measuring IADL, and patients completed six neurocognitive measures. Patient-proxy difference scores in IADL were compared between patients who were defined as neurocognitively impaired (≥2 neurocognitive measures ≥2.0 standard deviations below healthy controls) and non-neurocognitively impaired. With multinomial logistic regression analyses we examined if neurocognitive variables were independently associated with patient-proxy disagreement in IADL ratings. Results Patients (n = 81) did not systematically (P < .01) rate IADL outcomes different than their proxies. Proxies did report more problems on 19/32 individual items and all five scales. This effect was more apparent in dyads with a neurocognitively impaired patient (n = 37), compared to dyads with non-neurocognitively impaired patients (n = 44). Multinomial logistic regression analyses showed that several neurocognitive variables (e.g., cognitive flexibility and verbal fluency) were independently associated with disagreement between patients and proxies on different scales. Conclusion Neurocognitive deficits seem to play a role in the discrepancies between brain tumor patients and their proxies assessment of patient’s level of IADL. Although replication of our results is needed, our findings suggests that caution is warranted in interpreting self-reported IADL by patients with neurocognitive impairment, and that such self-reports should be supplemented with proxy ratings.

Funder

European Organisation for Research and Treatment of Cancer

Publisher

Oxford University Press (OUP)

Subject

Medicine (miscellaneous)

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3